Company news
China Resources Double-Crane Pharmaceutical Co., Ltd. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
(600062)"China Resources Double-Crane Pharmaceutical Co., Ltd."Announcement on Obtaining Drug Registration Certificate by the Company and Its Subsidiaries for Certain Drugs
November 3, 2026
(600062)"China Resources Double-Crane Pharmaceutical Co., Ltd."Announcement on Receipt of the Approval Notice for the Supplementary Drug Application for Perindopril Amlodipine Tablets (Ⅲ) by the Controlled Subsidiary Shuanghe Tian'an Pharmaceutical (Guizhou) Co., Ltd.
November 2, 2026
(600062)"China Resources Double-Crane Pharmaceutical Co., Ltd."Announcement on Passing the Drug GMP Compliance Inspection by the Controlled Subsidiary Henan Zhongshuai Pharmaceutical Sci & Tech Co., Ltd.
November 2, 2026
(600062)"China Resources Double-Crane Pharmaceutical Co., Ltd."Report for Q3 2026
October 27, 2026
(600062)"China Resources Double-Crane Pharmaceutical Co., Ltd."Announcement on the Workshop Construction Project of the Controlled Subsidiary Shenzhou Biology & Technology Co., Ltd.
October 27, 2026
(600062)"China Resources Double-Crane Pharmaceutical Co., Ltd."Announcement on Satisfaction of Conditions for Lifting of Restrictions for the 3rd Lifting Period of the Reserved Grant under the 2021 Restricted Share Incentive Plan
October 27, 2026
(600062)"China Resources Double-Crane Pharmaceutical Co., Ltd."Announcement on Resolutions of the 24th Meeting of the 10th Board of Directors
October 27, 2026
(600062)"China Resources Double-Crane Pharmaceutical Co., Ltd."Announcement on Progress of Major Asset Restructuring
October 27, 2026
(600062)"China Resources Double-Crane Pharmaceutical Co., Ltd."Announcement on Key Operating Data for the First Three Quarters of 2026
October 27, 2026
(600062)"China Resources Double-Crane Pharmaceutical Co., Ltd."Announcement on Convening the Q3 2026 Performance Briefing
October 23, 2026
(600062)"China Resources Double-Crane Pharmaceutical Co., Ltd."Announcement on Obtaining the Drug Registration Certificate for Baricitinib Tablets by the Wholly-owned Subsidiary Beijing Wanhui Double-Crane Pharmaceutical Co., Ltd.
October 20, 2026
(600062)"China Resources Double-Crane Pharmaceutical Co., Ltd."Announcement on Obtaining the Drug Registration Certificate for Composite Potassium Hydrogen Phosphate Injection by the Wholly-owned Subsidiary Anhui Double-Crane Pharmaceutical Co., Ltd.
October 19, 2026
(600062)"China Resources Double-Crane Pharmaceutical Co., Ltd."Announcement on Mycophenolate Mofetil for Injection of the Wholly-owned Subsidiary Double-Crane Pharmaceutical (Hainan) Co., Ltd. Passing the Consistency Evaluation of Quality and Efficacy for Generic Drugs
October 15, 2026
(600062)"China Resources Double-Crane Pharmaceutical Co., Ltd."Announcement on Obtaining U.S. FDA Clinical Trial Approval for DC7001A Capsules by Wholly-owned Subsidiary Beijing Double-Crane Runchuang Technology Co., Ltd.
October 11, 2026
(600062)"China Resources Double-Crane Pharmaceutical Co., Ltd."Announcement on Obtaining the Approval Notice for Marketing Application of the Chemical API Vortioxetine Hydrobromide by the Controlled Subsidiary China Resources Double-Crane Xiangzhong Pharmaceutical (Hunan) Co., Ltd.
October 11, 2026
Announcement on Obtaining the Approval Notice for Marketing Application of the Chemical API Brexpiprazole by the Controlled Subsidiary China Resources Double-Crane Xiangzhong Pharmaceutical (Hunan) Co., Ltd.
September 28, 2026
(600062)"China Resources Double-Crane Pharmaceutical Co., Ltd."Announcement on Progress in Major Asset Restructuring
September 27, 2026
Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026
September 27, 2026
Announcement on Propranolol Hydrochloride Injection of the Wholly-owned Subsidiary China Resources Zizhu Pharmaceutical Co., Ltd. Passing the Consistency Evaluation of Quality and Efficacy for Generic Drugs
September 23, 2026
Announcement on Obtaining the Drug Registration Certificate for Ezetimibe and Atorvastatin Calcium Tablets by the Wholly-owned Subsidiary China Resources Saike Pharmaceutical Co., Ltd.
September 14, 2026
Notice on Convening the 2nd Extraordinary General Meeting in 2026
September 8, 2026
Announcement on Obtaining the Drug Registration Certificate for Lomustine Capsules
September 1, 2026
Announcement on the Obtaining of the Drug Registration Certificate for Oxcarbazepine Tablets by the Controlled Subsidiary, China Resources Double-Crane Xiangzhong Pharmaceutical (Hunan) Co., Ltd.
August 31, 2026
Announcement on Progress in Major Asset Restructuring
August 28, 2026
Announcement on the Profit Distribution Plan for the First Half of 2026
August 21, 2026
Announcement on the Obtaining of the Drug Registration Certificate for Lidocaine Hydrochloride Gel
August 18, 2026
Announcement on Obtaining Drug Registration Certificate for Sodium Lactate Ringer's Irrigation Solution by Wholly-owned Subsidiary Shanghai Changzheng Fumin Jinshan Pharmaceutical Co., Ltd.
August 13, 2026
Announcement on Receipt of the Notice of Approval for Clinical Trial of DC7001A Capsules by Wholly-owned Subsidiary Beijing Double-Crane Runchuang Technology Co., Ltd.
August 12, 2026
Announcement on Obtaining Drug Registration Certificate for Acetazolamide Sustained‑release Capsules by the Controlled Subsidiary Henan Zhongshuai Pharmaceutical Sci & Tech Co., Ltd.
August 11, 2026
Announcement on Completion of the Phase III Clinical Trial of Pregabalin Sustained-Release Tablets by Wholly-owned Subsidiary China Resources Double-Crane Limin Pharmaceutical (Jinan) Co., Ltd.
August 6, 2026
Announcement on Repurchase of Relevant Rights and Interests in Perfluoropropane Lipid Microsphere Injection by the Partner
August 4, 2026
Announcement on the Proposed Selection of Certain Drugs of the Company in the National Centralized Drug Procurement
August 3, 2026
Announcement on Implementation of Dividend Distribution for 2025
July 21, 2026
Announcement on Participation in the Public Bidding for Shares of Lier Chemical Co., Ltd.
July 15, 2026
Announcement on Obtaining Drug Registration Certificate for Progesterone Soft Capsules by Wholly-owned Subsidiary Shanxi Jinxin Double-Crane Pharmaceutical Co., Ltd.
July 3, 2026
Announcement on Obtainment of CEP Certificate for Sodium Valproate API by Holding Subsidiary China Resources Double-Crane Pharmaceutical (Hunan) Co., Ltd.
July 1, 2026
Announcement on Progress in Acquiring 100% Equity in Nanjing Xinbai Pharmaceutical Co., Ltd. and Completion of Industrial and Commercial Change Registration
June 25, 2026
Announcement on Obtaining Drug Registration Certificate for Some Drugs by Subsidiary
June 16, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
June 8, 2026
Announcement on Renewing Engagement of Accounting Firm
May 18, 2026
Announcement on Wholly-owned Subsidiary China Resources Saike Pharmaceutical Co., Ltd. Obtaining the Drug Registration Certificate for Ezetimibe Tablets
May 11, 2026
Announcement on Wholly-owned Subsidiary Anhui Double-Crane Pharmaceutical Co., Ltd. Obtaining the Drug Registration Certificate for Sodium, Potassium, Magnesium and Calcium Concentrated Solution for Injection
May 8, 2026
Announcement on Completion of Phase III Drug Clinical Trial
April 28, 2026
Announcement on Acquiring 100% Equity of Nanjing Xinbai Pharmaceutical Co., Ltd. and Related Party Transactions
April 24, 2026
Announcement on ObtainingApproval Notice for the Supplementary Application of Drug for Dienogest Tablets by Wholly-owned Subsidiary China Resources Zizhu Pharmaceutical Co., Ltd.
April 21, 2026
Announcement on Convening the Q1 2026 Performance Briefing
April 20, 2026
Announcement on Lifting Sales Restrictions and Circulation of Restricted Stocks in 3rd Lifting Period of Initially Granted Part under Restricted Stock Incentive Plan of 2021
April 14, 2026
Announcement on Obtaining Approval Notice for Drug Supplement Application by Wholly-Owned Subsidiary Xi'an Jingxi Double-Crane Pharmaceutical Co., Ltd. for Mannitol Injection
April 7, 2026
Announcement on Changing Registered Capital and Amending the Articles of Association
March 19, 2026
Announcement on Obtaining Drug Registration Certificate for Sodium Valproate Oral Solution by Holding Subsidiary Hunan Xiangzhong Pharmaceutical Co., Ltd.
March 17, 2026